Antisense Therapy Tominersen Holds Promise in Huntington Disease
The drug successfully demonstrated an ability to reduce mutant huntingtin protein, but the clinical benefits of that effect are yet to be determined.
PARP Pathway May Hold Promise for Parkinson Disease Treatment
Examining the underlying roles of poly adenosine diphosphate-ribose (PARP) play in the neurodegeneration of Parkinson disease.
The Evolving Landscape of Migraine Treatment
The assistant professor of Neurology, Concussion and Headache Medicine divisions, Mayo Clinic, Scottsdale, Arizona discussed the evolving migraine treatment landscape and how they have been incorporated into her practice.
Neuromodulation Holds Promise in Alzheimer Disease
Will ethical considerations and lack of consent stand in the way of thoroughly exploring the potential of this nondrug therapy?
The Great Debate: Can Older Patients With MS Discontinue Therapy?
As the treatment of multiple sclerosis continues to evolve and improve, the proposition of lifetime therapy has come under scrutiny.
Treating Tuberous Sclerosis: A Time to Shine for a Rare Disease
Elizabeth Thiele, MD, PhD, answers a variety of questions on treating tuberous sclerosis, and the landscape of treatments available at this time.
Building the Foundation for Precision Medicine in Epilepsy
Significant advancements in genetics and the implementation of artificial intelligence have begun to carve a new, more personalized path for the diagnosis and treatment of seizure disorders.
REM Sleep Behavior Disorder: Predicting Conversion to Synucleinopathy
As a marker of impending neurodegeneration, urgency surrounds efforts to slow or stop the progression of REM sleep behavior disorder.
2 Clarke Drive Cranbury, NJ 08512